Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
US5162111A · kind A · utility
22Cited by
1References
16Claims
0Family size
Inventors
Key dates
| Filing date | Jul 30, 1986 |
| Grant date | Nov 10, 1992 |
| Priority date | — |
| Expiry date | Jul 30, 2006 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/145
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Subjects suffering from infectious diseases are treated by direct administration of therapeutically-effective quantities of granulocyte-macrophage colony stimulating factor employed by itself or in conjunction with an antibiotic or a sulfonamide or other immunologically effective therapeutic agents. Homogeneous granulocyte-macrophage colony stimulating factor for use in treatment in bacterial diseases is prepared by recombinant DNA techniques and then purified to homogeneity by reverse phase high-performance liquid chromatography so that it may be safely administered to subject's suffering from infectious diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.